HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TARS
Tarsus Pharmaceuticals, Inc.
TARS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TARS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Unavailable |
TARS's revenue and cash flow are currently healthy, but its profitability is weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TARS PE Valuation
TARS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TARS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
TARS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TARS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$15.16 | -$13.17 |
| Q2 2026 | -$1.06 | +$1.24 |
| Q1 2026 | -$1.11 | +$1.59 |
| Q4 2025 | -$1.59 | +$1.48 |
| Q3 2025 | -$1.99 | +$1.80 |
| Q2 2025 | -$2.30 | +$2.16 |
| Q1 2025 | -$2.70 | +$2.05 |
| Q4 2024 | -$3.07 | +$1.55 |
TARS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over TARS on profitability, with a higher operating margin.
TARS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $194.6M | +64% |
| Q2 2026 | $173.9M | +69% |
| Q1 2026 | $162.1M | +107% |
| Q4 2025 | $151.7M | +128% |
| Q3 2025 | $118.7M | +147% |
| Q2 2025 | $102.7M | +152% |
| Q1 2025 | $78.3M | +184% |
| Q4 2024 | $66.4M | +408% |
TARS has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -340% | -328 points |
| Q2 2026 | -11% | +10 points |
| Q1 2026 | -3.8% | +30 points |
| Q4 2025 | -5.3% | +32 points |
| Q3 2025 | -12% | +40 points |
| Q2 2025 | -22% | +60 points |
| Q1 2025 | -34% | +103 points |
| Q4 2024 | -37% | +303 points |
TARS's operating margin was −340% last quarter, down 328 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TARS on cash flow, with more consistent year-over-year improvement.
TARS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.2M | -144% |
| Q2 2026 | $57.2M | +$87.5M |
| Q1 2026 | -$30.5M | -$9.2M |
| Q4 2025 | $13M | +$35.2M |
| Q3 2025 | $16.3M | +$25.3M |
| Q2 2025 | -$30.4M | -$14.9M |
| Q1 2025 | -$21.2M | +$16.7M |
| Q4 2024 | -$22.3M | +$17.1M |
TARS's free cash flow has turned positive after six years mostly in the red: $32M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TARS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TARS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +3M shares |
| 1 year | +9% | +3.8M shares |
| 3 years | +52% | +15.8M shares |
| 5 years | +125% | +25.8M shares |
| Available history | +326% | +35.5M shares |
TARS has 46M diluted shares, up 9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | $1,000 |
| Q1 2020 | $27,000 |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TARS Net Leverage
TARS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TARS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.0 | Neutral |
| Stochastic | 44.3 | Neutral |
TARS's weekly RSI is 56 (neutral) and its Stochastic is 44 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TARS PE vs Healthcare Sector
TARS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TARS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.3 | 6.3% above |
| 20 week MA | $70.3 | 9.4% above |
| 50 week MA | $69.2 | 11% above |
| 100 week MA | $60.9 | 26% above |
| 200 week MA | $42.9 | 79% above |
TARS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TARS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.6 | $44.0 | +114% |
| 2021 | $44.0 | $25.9 | -41% |
| 2022 | $25.9 | $14.5 | -44% |
| 2023 | $14.5 | $20.3 | +40% |
| 2024 | $20.3 | $55.0 | +172% |
| 2025 | $55.0 | $81.8 | +49% |
| 2026 YTD | $81.8 | $76.9 | -6% |
TARS has the edge over HIMS on returns for 2026, with the stronger performance.